Comparative therapeutic efficacy of clinafloxacin in a pneumococcal meningitis mouse model

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 4, 2000, Pages 489-492

  Shapiro, Martin A ^a   Donovan, Kurt D ^a   Gage, Jeffrey W ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; CLINAFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MENINGITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; STREPTOCOCCUS PNEUMONIAE;

EID: 0034078471     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/45.4.489     Document Type: Article

References (11)

1. Centers for Disease Control and Prevention. (1998). Bacterial Meningitis. [Online]. Division of Bacterial and Mycotic Diseases. http://www.cdc.gov/ncidod/dbmd/diseaseinfo/meningitis_g.htm. [Updated 21 September 1999].
2. Lund, B. C., Ernst, E. J. & Klepser, M. E. (1998). Strategies in the treatment of penicillin-resistant Streptococcus pneumonias. American Journal of Health-System Pharmacy 55, 1987-94.
3. Bradley, J. S. & Scheld, W. M. (1997). The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Clinical Infectious Diseases 24 Suppl. 2, S213-21.
4. Sloas, M. M., Barrett, F. F., Chesney, P. J., English, B. K., Hill, B. C., Tenover, F. C. et al. (1992). Cephalosporin treatment failure in penicillin-and cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatric Infectious Disease Journal 11, 662-6.
5. Stein, G. E. (1996). Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clinical Infectious Diseases 23, Suppl. 1, S19-24.
6. Jorgensen, H., Weigel, L. M., Ferraro, M. J., Swenson, J. M. & Tenover, F. C. (1999). Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates, including those with mutations in the gyrA, parC, and parE loci. Antimicrobial Agents and Chemotherapy 43, 329-34.
7. National Committee for Clinical Laboratory Standards. (1990). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Second Edition: Approved Standard M7-A2. NCCLS, Villanova, PA.
8. Haley, J. T. & McCormick, W. G. (1957). Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. British Journal of Pharmacology 12, 12-5.
9. Hubert, J. J., Bohidar, N. R. & Peace, K. E. (1988). Assessment of pharmacological activity. In Biopharmaceutical Statistics for Drug Development (Peace, K. E., Ed.), pp. 83-145. Marcel Dekker, New York.
10. Friedland, I. R., Paris, M., Ehrett, S., Hickey, S., Olsen, K. & McCracken, G. H. (1993). Evaluation of antimicrobial regimens for the treatment of experimental penicillin-and cephalosporin-resistant pneumococcal meningitis. Antimicrobial Agents and Chemotherapy 37, 1630-6.
11. Ostergaard, C., Sorensen, T. K., Knudsen, J. D. & Frimodt-Moller, N. (1998). Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. Antimicrobial Agents and Chemotherapy 42, 1706-12.